Ginkgolide With Intravenous Alteplase Thrombolysis in Acute Ischemic Stroke Neurological Improving Trial

Summary

Previous clinical studies have confirmed that revascularization or recanalization rate after intravenous thrombolysis is closely related to the formation of thrombus, which also results in poor neurological function after thrombolysis. Platelet activating factor (PAF) strong platelet aggregation may be involved in thrombosis. Formation process. The main components of Ginkgolide injection (Ginkgo) are ginkgolide, ginkgolides A, ginkgolides B and ginkgolides C. Ginkgo biloba lactone can antagonize PAF and has strong anti-platelet aggregation. . Therefore, it can be speculated that ginkgolides injection combined with alteplase intravenous thrombolysis may improve the recanalization rate after thrombolysis and reduce the reocclusion rate.

In addition, clinical studies have also found that ginkgolide injection has a good auxiliary effect on hypertensive intracerebral hemorrhage, which can regulate inflammatory factors such as IL-6, TNF-α and high-sensitivity C-reactive protein (CRP) in patients. Recovery of neurological function in patients. It is well known that TNF-α, IL-β, IL-1, IL-6, IFN-γ, etc. are all inflammatory factors associated with reperfusion injury. Therefore, we speculate that ginkgolides injection may also regulate inflammatory factors associated with reperfusion injury, such as IL-6, TNF-α, thereby reducing reperfusion injury, thereby improving patient prognosis.

The aim of this study was to determine the clinical efficacy of ginkgolides injection combined with alteplase in the treatment of acute ischemic stroke, and to improve the prognosis of patients with thrombolysis.

Conditions

• Intravenous Alteplase Thrombolysis
• Neurological Improving

Interventions

DRUG

ginkgolide

ginkgolide plus alteplase

Sponsors & Collaborators

• Dongyang People's Hospital

  collaborator OTHER

• Haiyan People's Hospital

  collaborator UNKNOWN

• The Second Affiliated Hospital of Jiaxing University

  collaborator OTHER

• Tongxiang Second People's Hospital

  collaborator UNKNOWN

• Tongxiang First People's Hospital

  collaborator UNKNOWN

• Changxing People's Hospital

  collaborator OTHER

• The Central Hospital of Lishui City

  collaborator OTHER

• The First People's Hospital of Huzhou

  collaborator OTHER

• Taizhou First People's Hospital

  collaborator OTHER

• Second Affiliated Hospital, School of Medicine, Zhejiang University

  lead OTHER

Principal Investigators

• Ze Xin Chen · 2nd affiliated hospital of Zhejiang University，School of Medicine

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-07-31

Primary Completion

2020-05-01

Completion

2021-12-31

Countries

• China

Study Locations